Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$114.76 USD
+0.45 (0.39%)
Updated Dec 24, 2024 01:00 PM ET
After-Market: $114.72 -0.04 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum D VGM
Abbott (ABT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$132.95 | $149.00 | $117.00 | 15.85% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for Abbott comes to $132.95. The forecasts range from a low of $117.00 to a high of $149.00. The average price target represents an increase of 15.85% from the last closing price of $114.76.
Analyst Price Targets (22)
Find the top stocks with the greatest price target potential and Zacks Rank of 1 or 2
Broker Rating
Abbott currently has an average brokerage recommendation (ABR) of 1.58 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 24 brokerage firms. The current ABR compares to an ABR of 1.58 a month ago based on 24 recommendations.
Of the 24 recommendations deriving the current ABR, 16 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.67% and 8.33% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 8.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 16 | 16 | 15 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 6 | 6 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.58 | 1.58 | 1.58 | 1.58 | 1.61 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
12/13/2024 | Not Identified | Not Identified | Hold | Hold |
11/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/17/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Strong Buy |
10/17/2024 | Goldman Sachs | David H Roman | Strong Buy | Strong Buy |
10/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/17/2024 | Atlantic Equities | Issie Kirby | Hold | Hold |
10/17/2024 | UBS | Danielle Antalffy | Strong Buy | Strong Buy |
10/14/2024 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
10/8/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
10/8/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
10/1/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
9/29/2024 | Not Identified | Not Identified | Hold | Hold |
9/24/2024 | BTIG | Marie Thibault | Strong Buy | Strong Buy |
9/19/2024 | Piper Sandler | Adam C Maeder | Not Available | Strong Buy |
9/15/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Strong Buy |
9/2/2024 | Not Identified | Not Identified | Hold | Hold |
8/26/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Hold | Hold |
8/22/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/24/2024 | Daiwa America | Narumi Nakagiri | Not Available | Strong Buy |
7/19/2024 | William Blair | Margaret K Andrew | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.58 |
ABR (Last week) | 1.58 |
# of Recs in ABR | 24 |
Average Target Price | $132.95 |
LT Growth Rate | 9.10% |
Industry | Medical - Products |
Industry Rank by ABR | 78 of 251 |
Current Quarter EPS Est: | 1.34 |
ABT FAQs
Abbott Laboratories (ABT) currently has an average brokerage recommendation (ABR) of 1.58 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 24 brokerage firms.
The average price target for Abbott Laboratories (ABT) is $132.95. The current on short-term price targets is based on 10 reports.
The forecasts for Abbott Laboratories (ABT) range from a low of $117 to a high of $149. The average price target represents a increase of $15.85 from the last closing price of $114.76.
The current UPSIDE for Abbott Laboratories (ABT) is 15.85%
Based on short-term price targets offered by 22 analysts, the average price target for Abbott comes to $132.95. The forecasts range from a low of $117.00 to a high of $149.00. The average price target represents an increase of 15.85% from the last closing price of $114.76.